Background: The Lebanese Society of Infectious Diseases and Clinical Microbiology (LSIDCM), the Lebanese Society of Critical Care Medicine (LSCCM), and the Lebanese Pulmonary Society (LPS) play a major role in guiding clinicians across Lebanon in prescribing antibiotics for the management of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Members of these societies have tailored the international recommendations for the management of HAP/VAP to local epidemiological and microbiological data. The aims of these local guidelines are to guide clinicians in the prevention of VAP, selection of appropriate empiric and targeted antimicrobial regimens for VAP/HAP and to contribute to improving patient outcomes. Methods: Recommendations in these guidelines are adapted from international guidelines and are modeled based on locally-derived epidemiological and microbiological data, as well as the availability of antimicrobial agents and other resources. Results: These guidelines aim to combine both clinical and bacteriological strategies to appropriately diagnose and manage HAP/VAP. They recommend implementing evidence-based preventive measures to lower the rate of VAP and improve patient outcomes. The recommended duration of treatment with antibiotics in general should not exceed 7 days in patients with HAP whereas it should be 7–8 days in patients with VAP. Imunnosuppressed patients with Pseudomonas aeruginosa infection might require longer courses. Ceftolozane/tazobactam (CFT/TAZ) and ceftazidime/avibactam (CAZ/AVI) are considered good options in patients with HAP/VAP caused by extended spectrum beta-lactamase-producing Enterobacterales and multidrug-resistant Pseudomonas aeruginosa. They also play a key role in the implementation of a carbapenem-sparing strategy in an antimicrobial stewardship program. Conclusion: These guidelines represent a major step towards establishing Lebanese national guidelines for the management of HAP/VAP. They also emphasize on timeliness and appropriateness of antibiotic therapy for the management of HAP/VAP.